SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-004472 to Surrozen, Inc./DE (SRZN)

Surrozen, Inc./DE
Date: April 23, 2024 · CIK: 0001824893 · Accession: 0000000000-24-004472

AI Filing Summary & Sentiment

File numbers found in text: 333-278800

Date
April 23, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Surrozen, Inc./DE

Letter

United States securities and exchange commission logo April 23, 2024 Craig Parker President and Chief Executive Officer Surrozen, Inc. 171 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 Re:Surrozen, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278800 Dear Craig Parker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John T. McKenna

Show Raw Text
United States securities and exchange commission logo
April 23, 2024
Craig Parker
President and Chief Executive Officer
Surrozen, Inc.
171 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
Re:Surrozen, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No. 333-278800
Dear Craig Parker:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       John T. McKenna